Sumary of Study: Nearly one in five patients with malignant pleural mesothelioma contracted COVID-19:
- Nearly one in five patients with malignant pleural mesothelioma (MPM) at a Barcelona hospital contracted COVID-19 during the pandemic.
- In addition, those patients suffered a 75% mortality rate, according to research presented today during MA04: Current Status and Future Prospects of Pleural Mesothelioma and Thymoma at the IASLC 2021 World Conference on Lung Cancer.
- Malignant pleural mesothelioma is an aggressive pleural tumor associated with asbestos exposure and with limited survival despite systemic therapy.
- Patients with cancer or thoracic malignancies may be particularly affected by COVID-19. The TERAVOLT registry evaluated the effect of SARS-CoV-2 infection on patients with thoracic malignancies but included only eight patients with malignant pleural mesothelioma.
- In a recent study of COVID-19 and mortality in the United States, malignant pleural mesothelioma was significantly associated with increased odds for worse outcomes.
- To study the effect of COVID-19 infection on patients with malignant pleural mesothelioma Dr. Susana Cedres of Vall d´Hebron University Hospital and the Institute of Oncology, Barcelona, Spain, analyzed the medical records of 38 patients with malignant pleural mesothelioma.
- Dr. Cedres collected clinical data including demographics, comorbidities, oncological background, and COVID-19 illness status.
- “Of the 38 patients with malignant pleural mesothelioma at our institution in this pandemic era, seven were diagnosed with COVID-19 infection (18%) by a positive RT-PCR,” she reported.